Acceleron Pharma has raised a $30M private financing. Celgene, one of Acceleron’s strategic partners, and all other existing investors participated in this financing. The proceeds will be used to expand and advance Acceleron’s clinical stage pipeline and to continue to support its highly productive research engine.

“This fortifies Acceleron’s solid financial position and provides the company with the resources to continue to advance and expand our robust clinical and preclinical pipeline”, said John Knopf, Ph.D., chief executive officer of Acceleron. “We’re especially pleased with Celgene’s commitment to Acceleron as we jointly develop several promising products for the treatment of anemia.”